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Abstract 
Transdermal drug delivery is defined as self contained, discrete dosage form which, when applied to the intact 
skin, deliver the drug, through the skin at controlled rate to the systemic circulation. Despite their relatively 
higher costs, transdermal delivery systems have proved to be advantageous for delivery of selected drugs such 
as estrogens, testosterone, clonidine, nitroglycerin, scopolamine, fentanyl, and nicotine. The transdermal route 
has numerous advantages over the more traditional drug delivery routes. These include high bioavailability, 
absence of first pass hepatic metabolism, steady drug plasma concentrations, and the fact that therapy is non-
invasive.  Both topical and transdermal drug products are intended for external use. However, topical 
dermatologic products are intended for localized action on one or more layers of the skin [e.g.Sunscreens, 
keratolytic agents, local anesthetics, antiseptics and anti-inflammatory agents]. Although some medication from 
these topical products may unintentionally reach systemic circulation, it is usually in sub-therapeutic 
concentrations, and does not produce effects of any major concern except possibly in special situations, such as 
the pregnant or nursing patient. On the other hand, transdermal drug delivery systems use the percutaneous 
route for systemic drug delivery. To provide continuous drug infusion through an intact skin, several 
transdermal therapeutic systems have been developed for topical application onto the intact skin surface to 
control the delivery of drug and its subsequent permeation through the skin tissue. 
Keywords: Transdermal, Patches, Dosage forms, Nitroglycerin, Nicotine 
Corresponding Author:  
Archana Sharma,  
Department of Pharmaceutical Chemistry,   




Please cite this article in press as Archana Sharma et al, Transdermal Drug Delivery: A Way for Better 












IAJPS 2017, 4 (10), 3675-3687                Archana Sharma et al                  ISSN 2349-7750 





Transdermal drug delivery is defined as self 
contained, discrete dosage forms which, when 
applied to the intact skin, deliver the drug, through 
the skin at controlled rate to the systemic 
circulation. Transdermal drug delivery system 
[TDDS] established itself as an integral part of 
novel drug delivery systems. From 1979, when the 
Food and Drug Administration approved the first 
transdermal drug delivery system [Transderm Scop
 
Patch], to the current transdermal delivery systems, 
there evolved a successful alternative to systemic 
drug delivery. Despite their relatively higher costs, 
transdermal delivery systems have proved 
advantageous for delivery of selected drugs, such 
as estrogens, testosterone, clonidine, nitroglycerin, 
scopolamine, fentanyl, and nicotine.The 
transdermal route has numerous advantages over 
the more traditional drug delivery routes. These 
include high bioavailability, absence of first pass 
hepatic metabolism, steady drug plasma 
concentrations, and the fact that therapy is non-
invasive.  Both topical and transdermal drug 
products are intended for external use. However, 
topical dermatologic products are intended for 
localized action on one or more layers of the skin 
[e.g.Sunscreens, keratolytic agents, local 
anesthetics, antiseptics and anti-inflammatory 
agents]. Although some medication from these 
topical products may unintentionally reach 
systemic circulation, it is usually in sub-therapeutic 
concentrations, and does not produce effects of any 
major concern except possibly in special situations, 
such as the pregnant or nursing patient. On the 
other hand, transdermal drug delivery systems use 
the percutaneous route for systemic drug delivery, 
but the skin is not the primary target organ. To 
provide continuous drug infusion through an intact 
skin, several transdermal therapeutic systems have 
been developed for topical application onto the 
intact skin surface to control the delivery of drug 
and its subsequent permeation through the skin 
tissue. It is exemplified by the development and 
marketing of scopolamine-releasing transdermal 
therapeutic system for 72-hr prophylaxis or 
treatment of motion-induced nausea, of 
nitroglycerin and isosorbide dinitrate-releasing 
trans-dermal therapeutic systems for once-a-day 
medication of angina pectoris , and of clonidine-
releasing transdermal therapeutic system for 
weekly treatment of hypertension . The intensity of 
interests in the potential biomedical applications of 
transdermal controlled drug administration is 
demonstrated in the increasing research activities in 
a number of health care institutions in the 
development of various types of transdermal 
therapeutic systems for long term continuous 
infusion of therapeutic agents, including 
antihypertensive, anti-anginal, anti-histamine, anti-
inflammatory, analgesic, anti-arthritic, steroidal, 
and contraceptive drugs. 
Advantages of Transdermal Drug Delivery 
Systems  
1. Transdermal medication delivers a steady 
infusion of a drug over an extended period of 
time. Adverse effects or therapeutic failures 
frequently associated with intermittent dosing 
can also be avoided.  
2. They can be used for drugs with narrow 
therapeutic window. 
3. Transdermal delivery can increase the 
therapeutic value of many drugs by avoiding 
specific problems associated with the drug e.g., 
gastro-intestinal irritation, low absorption, 
decomposition due to hepatic „‟first- pass” 
effect, formation of metabolites that cause side 
effects, short half - life necessitating frequent 
dosing etc  
4. Due to the above advantage, it is possible that 
an equivalent therapeutic effect can be elicited 
via transdermal drug input with a lower daily 
dose of the drug than is necessary, if, for 
example, the drug is given orally.  
5. The simplified medication regimen leads to 
improved patient compliance and reduced inter 
& intra – patient variability.  
6. At times the maintenance of the drug 
concentration within the diphase is not desired. 
Application and removal of transdermal patch 
produce the optimal sequence of 
pharmacological effect.  
7. Self administration is possible with these 
systems.  
8. The drug input can be terminated at any point 
of time by removing transdermal patch.  
 
Disadvantages of Transdermal Drug Delivery 
Systems 
1. The drug must have some desirable 
physicochemical properties for penetration 
through stratum corneum and if the drug dose 
required for therapeutic value is more than 10 
mg/day, the transdermal delivery will be very 
difficult.  
2. Only relatively potent drugs are suitable 
candidates for TDDS because of the natural 
limits of drug entry imposed by the skin 
impermeability.  
3. Some patients develop contact dermatitis at the 
site of application for one or more of the 
system components, necessitating 
discontinuation.  
4. Clinical need is another area that has to be 
examined carefully before a decision is made 
to develop a transdermal product.  
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5. The barrier function of the skin changes from 
one site to another on the same person, from 
person to person and with age.  
 
SKIN AS SITE OF DRUG INFUSION 
The skin of an average adult body covers a surface 
area of approximately two square meters and 
receives about one-third of the blood circulating 
through the body. The skin is a multilayered organ 
composed of many histological layers. It is 
generally described in terms of three major tissue 
layers: the epidermis, the dermis, and the 
hypodermis [Fig 1]. Microscopically, the epidermis 
further divided into five anatomical layers with 
stratum corneum forming the outer most layer of 
the epidermis, exposing to the external 
environment. An average human skin surface is 
known to contain, on the average, 40-70 hair 
follicles and 200-250 sweat ducts on each square 
centimeter of skin area. These skin appendages, 
however, actually occupy, grossly, only 0.1% of 
the total human skin surface. Even though the 
foreign agents, especially the water-soluble ones, 
may be able to penetrate into the skin via these skin 
appendages at a rate which is faster than through 
the intact area of the stratum corneum, this trans-
appendage route of percutaneous absorption has, at 
steady state, a very limited contribution to the 
overall kinetic profile of transdermal permeation. 
Therefore, the transdermal permeation of most 
neutral molecules can, thus, be considered as, a 
process of passive diffusion through the intact 
stratum corneum in the inter follicular region. So, 
for the sake of mechanistic analysis of transdermal 
drug infusion, the various skin tissue layers can be 
represented by a simplistic multilayer model. In the 
case that the skin serves as the point of 
administration for systemically active drugs, the 
drug applied topically will be absorbed, first into 
the systemic circulation and then transported to 
target tissues. 
MECHANISM OF TRANSDERMAL 
PERMEATION [3] 
For a systemically-active drug to reach a target 
tissue, it has to possess some physico-chemical 
properties which facilitate the absorption of the 
drug through the skin [Fig 1], and also the uptake 
of the drug by the capillary network in the dermal 
papillary layer The rate of permeation, dQ/dt, 
across various layers of skin tissues can be 
expressed as. 
 
dQ/dt  =  Ps [ Cd – Cr ]  --------          [1] 
Where, Cd and Cr are, respectively, the 
concentrations of skin penetrate in the donor phase 
[stratum corneum] and the receptor phase [systemic 
circulation]; and Ps is the overall permeability 
coefficient of the skin and is defined by 
Ps =  Ks Dss /Hs ------[2] 
Where,  
Ks    = Partition coefficient of the penetrant  
Dss = Apparent diffusivity of penetrant  
hs    = Thickness of skin 
Thus, permeability coefficient [PS] may be a 
constant since Ks; Dss and hs terms in equation [2] 
are constant under the given set of conditions.  
A constant rate of drug permeation achieved, if 
Cd>Cr, then the equation [1] may be reduced to  
   
dQ/dt  = Ps .Cd -----[3] 
 
And the rate of skin permeation [dQ/dt] becomes a 
constant, if the Cd value remains fairly constant 
throughout the course of skin permeation. To 
maintain the Cd at a constant value, it is critical to 
make the drug to be released at a rate [Rr] which is 
always greater than the rate of skin uptake [Ra], i. 
e., Rr>>Ra 
 Relationship between the rate of drug release 
[Rr] from a transdermal drug delivery system 
[TDDS] and the rate of drug uptake [Ra] by 
the skin. 
By doing so, the drug concentration on the skin 
surface [Cd] is maintained at a level which is 
always greater than the equilibrium [or saturation] 
solubility of the drug in the stratum corneum [Ces], 
i.e., Cd>>Ces; and a maximum rate of skin 
permeation [dQ/dt]m, as expressed by equation 
[4],is thus reached: 
 
[dQ/dt]m = Ps . Cse 
 
Apparently, the magnitude of [dQ/dt] m is 
determined by the skin permeability coefficient 
[PS] of the drug and its equilibrium solubility in the 
stratum corneum [Ces]. 
TYPES OF TRANSDERMAL PATCHES [1-5] 
 Single-layer Drug-in-Adhesive 
The Single-layer Drug-in-Adhesive system is 
characterized by the inclusion of the drug directly 
within the skin-contacting adhesive. In this 
transdermal system design, the adhesive not only 
serves to affix the system to the skin, but also 
serves as the formulation foundation, containing 
the drug and all the excipients under a single 
backing film. The rate of release of drug from this 
type of system is dependent on the diffusion across 
the skin. The intrinsic rate of drug release from this 
type of drug delivery system is defined by  
 
dQ/dT = Cr /1/Pm + 1/Pa 
 
Where Cr is the drug concentration in the 
reservoir compartment and Pa and P m are the 
permeability coefficients of the adhesive layer and 
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the rate controlling membrane, Pm is the sum of 
permeability coefficients simultaneous 
penetrations across the pores and the polymeric 
material. Pm and Pa, respectively, are defined as 
follows. 
Pm = Km/r. Dm  /hm 
Pa =   Ka/m. Da  /ha 
where Km/r and Ka/m are the partition 
coefficients for the interfacial partitioning of drug 
from the reservoir to the membrane and from the 
membrane to adhesive respectively; Dm and Da 
are the diffusion coefficients in the rate 
controlling membrane and adhesive layer, 
respectively; and hm and ha are the thicknesses of 
the rate controlling membrane and adhesive layer, 
respectively. 
 Multi-layer Drug-in-Adhesive 
The Multi-layer Drug-in-Adhesive is similar to the 
Single-layer Drug-in-Adhesive in that the drug is 
incorporated directly into the adhesive. However, 
the multi-layer encompasses either the addition of a 
membrane between two distinct drug-in-adhesive 
layers or the addition of multiple drug-in-adhesive 
layers under a single backing film. The rate of drug 
release in this system is defined by,  
              
dQ/dt =  Ka/r. Da  /Ha * Cr 
 
Where Ka/r is the partition coefficient for the 
interfacial partitioning of the drug from the 
reservoir layer to adhesive layer. 
 Drug Reservoir-in-Adhesive 
The Reservoir transdermal system design is 
characterized by the inclusion of a liquid 
compartment containing a drug solution or 
suspension separated from the release liner by a 
semi-permeable membrane and adhesive. The 
adhesive component of the product responsible for 
skin adhesion can either be incorporated as a 
continuous layer between the membrane and the 
release liner or in a concentric configuration around 
the membrane. The rate of drug release from this 
drug reservoir gradient controlled system is given 
by,  
           DQ/dt = Ka/r. Da  /ha[t] *A [ ha ] 
In the above equation, the thickness of the 
adhesive layer for drug molecules to diffuse 
through increases with time ha [t]. To compensate 
for this time dependent increase in the diffusional 
path due to the depletion of drug dose by release, 
the drug loading level is also increased with the 
thickness of diffusional path A [ha]. 
 
 
 Drug Matrix-in-Adhesive 
The Matrix system design is characterized by the 
inclusion of a semisolid matrix containing a drug 
solution or suspension which is in direct contact 
with the release liner. The component responsible 
for skin adhesion is incorporated in an overlay and 
forms a concentric configuration around the 
semisolid matrix. The rate of drug release from this 
type of system is defined as, 
 
DQ/dt = ACp Dp½ /2t 
 
Where A is the initial drug loading dose dispersed 
in the polymer matrix and Cp and Dp are the 
solubility and diffusivity of the drug in the polymer 
respectively. Since, only the drug species dissolved 
in the polymer can release, Cp is essentially equal 
to Cr, where Cris the drug concentration in the 
reservoir compartment. [8, 9] 
BASIC COMPONENT OF TDDS [1,2,8,11,12] 
 Polymer matrix / Drug reservoir  
 Drug  
 Permeation enhancers  
 Pressure sensitive adhesive [PSA]  
 Backing laminates  
 Release liner and other excipients like 
plasticizers and solvents  
 
1. Polymer matrix / Drug reservoir  
Polymers are the backbone of TDDS, which control 
the release of the drug from the device. Polymer 
matrix can be prepared by dispersion of drug in 
liquid or solid state synthetic polymer base. 
Polymers used in TDDS should have 
biocompatibility and chemical compatibility with 
the drug and other components of the system such 
as penetration enhancers and PSAs. Additionally 
they should provide consistent and effective 
delivery of a drug throughout the products intended 
shelf life and should be of safe status. Companies 
involved in the field of transdermal delivery 
concentrate on a few selective polymeric systems. 
For example, Alza Corporation mainly concentrates 
on ethylene vinyl acetate [EVA] copolymers or 
microporous polypropylene and Searle Pharmacia 
concentrates on silicon rubber. Similarly Colorcon, 
UK uses HPMC for matrix preparation for 
propranolol transdermal delivery and Sigma uses 
ethyl cellulose for isosorbide dinitrate matrix. The 
polymers utilized for TDDS can be classified as,  
 
Natural Polymers: e.g. cellulose derivatives, zein, 
gelatin, shellac, waxes, gums, natural rubber and 
chitosan etc.  
Synthetic Elastomers: e.g. polybutadiene, hydrin 
rubber, polyisobutylene, silicon rubber, nitrile, 
acrylonitrile, neoprene, butyl rubber etc.  
 
Synthetic Polymers: e.g. polyvinyl alcohol, 
polyvinylchloride, polyethylene, polypropylene, 
polyacrylate, polyamide, polyurea, 
polyvinylpyrrolidone, polymethylmethacrylate etc.  
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The polymers like cross linked polyethylene glycol, 
eudragits, ethyl cellulose, polyvinylpyrrolidone and 
hydroxypropylmethylcellulose are used as matrix 
formers for TDDS. Other polymers like EVA, 




The transdermal route is an extremely attractive 
option for the drugs with appropriate pharmacology 
and physical chemistry. Transdermal patches offer 
much to drugs which undergo extensive first pass 
metabolism, drugs with narrow therapeutic 
window, or drugs with short half life which causes 
non- compliance due to frequent dosing. The 
foremost requirement of TDDS is that the drug 
possesses the right mix of physicochemical and 
biological properties for transdermal drug delivery. 
It is generally accepted that the best drug 
candidates for passive adhesive transdermal 
patches must be non ionic, of low molecular weight 
[less than 500 Daltons], have adequate solubility in 
oil and water [log P in the range of 1-3], a low 
melting point [less than 200°C] and are potent 
[dose in mg per day]. Table 1 enlists the currently 
available drugs for transdermal delivery. In 
addition drugs like rivastigmine for Alzheimers and 
Parkinson dementia, rotigotine for Parkinson, 
methylphenidate for attention deficit hyperactive 
disorder and selegiline for depression are recently 
approved as TDDS.Drug must have 
Physicochemical properties [36] 
 The drug should have a molecular weight 
less than approximately 1000 daltons. 
 The drug should have affinity for both 
lipophilic and hydrophilic phases. 
Extreme portioning characteristics are 
not conducive to successful drug delivery 
via the skin. 
 The drug should have a low melting point. 
Biological properties [36] 
 The drug should be potent with a daily 
dose of the order of a few mg/day. 
 The half life [t1/2] of the drug should be 
short. 
 The drug must not induce a cutaneous 
irritant or allergic response. 
 Drugs which degrade in the GI tract or are 
inactivated by hepatic first pass effect are 
suitable candidates for trans-dermal 
delivery. 
 Tolerance to the drug must not develop 
under the near zero-order release profile of 
trans-dermal delivery. 
 Drugs which have to be administered for a 
long period of time or which cause 
adverse effects to non-target tissues can 
also be formulated for trans-dermal 
delivery. 
Permeation Enhancers [36] 
Three pathways are suggested for drug penetration 
through the skin: polar, non-polar, and polar/non-
polar. The enhancers act by altering one of these 
pathways. The key to altering the polar pathway is 
to cause protein conformational change or solvent 
swelling. The key to altering the nonpolar pathway 
is to alter the rigidity of the lipid structure and 
fluidize the crystalline pathway [this substantially 
increases diffusion]. The fatty acid enhancers 
increase the fluidity of the lipid portion of the 
Stratum Corneum. Some enhancers [binary 
vehicles] act on both polar and nonpolar pathways 
by altering the multilaminate pathway for 
penetrants. Enhancers can increase the drug 
diffusivity in the Stratum Corneum [SC] by 
dissolving the skin lipids or by denaturing skin 
proteins. The type of enhancer employed has a 
significant impact on the design and development 
of the product. The success of dermatological drug 
products that are intended for systemic drug 
delivery, such as the transdermal, depends on the 
ability of the drug to penetrate through the skin in 
sufficient quantities to achieve its desired 
therapeutic effect. The methods employed for 
modifying the barrier properties of the SC to 
enhance the drug penetration [and absorption] 
through the skin can be categorized as  
[1] Chemical and  
 [2] Physical methods of enhancement.[15] 
 
Chemical Enhancers 
Chemicals that promote the penetration of 
topically applied drugs are commonly referred 
to as accelerants, absorption promoters, or 
penetration enhancers. Chemical enhancers act 
by 
  
 Increasing the drug permeability through the 
skin by causing reversible damage to the SC.  
  Increasing [and optimizing] thermodynamic 
activity of the drug when functioning as co 
solvent.  
  Increasing the partition coefficient of the drug 
to promote its release from the vehicle into the 
skin.  
 Conditioning the SC to promote drug 
diffusion.  
 Promoting penetration and establish drug 
reservoir in the SC.  
 
Physical enhancers 
The iontophoresis and ultra sound [also known as 
phonophoresis or sonophoresis] techniques are 
examples of physical means of enhancement that 
have been used for enhancing percutaneous 
penetration [and absorption] of various therapeutic 
agents. 
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Pressure sensitive adhesives 
 A PSA is a material that helps in maintaining an 
intimate contact between transdermal system and 
the skin surface. It should adhere with not more 
than applied finger pressure, be aggressively and 
permanently tachy, and exert a strong holding 
force. Additionally, it should be removable from 
the smooth surface without leaving a residue. 
Polyacrylates, polyisobutylene and silicon based 
adhesives are widely used in TDDSs. The selection 
of an adhesive is based on numerous factors, 
including the patch design and drug formulation. 
For matrix systems with a peripheral adhesive, an 
incidental contact between the adhesive and the 
drug and penetration enhancer should not cause 
instability of the drug, penetration enhancer or the 
adhesive. In case of reservoir systems that include a 
face adhesive, the diffusing drug must not affect 
the adhesive. In case of drug-in-adhesive matrix 
systems, the selection will be based on the rate at 
which the drug and the penetration enhancer will 
diffuse through the adhesive. Ideally, PSA should 
be physic chemically and biologically compatible 
and should not alter drug release. 
 
Backing Laminate 
While designing a backing layer, the consideration 
of chemical resistance of the material is most 
important. Excipients compatibility should also be 
considered because the prolonged contact between 
the backing layer and the excipients may cause the 
additives to leach out of the backing layer or may 
lead to diffusion of excipients, drug or penetration 
enhancer through the layer. However, an 
overemphasis on the chemical resistance may lead 
to stiffness and high occlusive to moisture vapor 
and air, causing patches to lift and possibly irritate 
the skin during long wear. The most comfortable 
backing will be the one that exhibits lowest 
modulus or high flexibility, good oxygen 
transmission and a high moisture vapor 
transmission rate. Examples of some backing 




During storage the patch is covered by a protective 
liner that is removed and discharged immediately 
before the application of the patch to skin. It is 
therefore regarded as a part of the primary 
packaging material rather than a part of dosage 
form for delivering the drug. However, as the liner 
is in intimate contact with the delivery system, it 
should comply with specific requirements 
regarding chemical inertness and permeation to the 
drug, penetration enhancer and water. Typically, 
release liner is composed of a base layer which 
may be non-occlusive [e.g. paper fabric] or 
occlusive [e.g. polyethylene, polyvinylchloride] 
and a release coating layer made up of silicon or 
Teflon. Other materials used for TDDS release 




Various solvents such as chloroform, methanol, 
acetone, isopropanol and dichloromethane are used 
to prepare drug reservoir. In addition plasticizers 
such as dibutylpthalate, triethylcitrate, polyethylene 
glycol and propylene glycol are added to provide 
plasticity to the transdermal patch. 
 
APPROACHES TO DEVELOP TD SYSTEMS 
[2,8,11,12] 
Several technologies have been successfully 
developed to provide a rate control over the   
release and the transdermal permeation of drugs. 
These technologies can be classified into four 
approaches as follows: 
1.  Membrane permeation – controlled 
systems  
2.  Adhesive dispersion – type systems.  
3.  Matrix diffusion – controlled systems.  
4.  Micro reservoir type or micro sealed 
dissolution controlled systems.  
 
1. Membrane Permeation – Controlled Systems 
In this type of system, drug reservoir is 
encapsulated in a shallow compartment moulded 
from a drug-impermeable metallic plastic laminate 
and a rate controlling polymeric membrane which 
may be micro porous or non-porous. The drug 
molecules are permitted to release only through the 
rate – controlling polymeric membrane. In the drug 
reservoir compartment, the drug solids are either 
dispersed homogenously in a solid polymer matrix 
[e.g. Polyisobutylene adhesive] or suspended in an 
unbleachable, viscous liquid medium [e.g. Silicon 
fluids] to form a paste like suspension. The rate of 
drug release from this type of system can be 
tailored by varying the polymer composition, 
permeability coefficient and thickness of the rate 
limiting membrane and adhesive. The constant 
release rate of the drug is the major advantage of 
membrane permeation controlled system. However, 
a rare risk also exists when an accidental breakage 
of the rate controlling membrane can result in dose 
dumping or rapid release of entire drug content. 
Examples of this system are 
 
Transderm – Nitro  
Nitroglycerin – releasing transdermal system for 
once a day medication in angina pectoris.  
 
Transderm – Scop  
Scopolamine – releasing transdermal system for 72 
hrs. Prophylaxis of motion                                                                   
sickness.  
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Clonidine-releasing transdermal system for 7 day 
therapy of hypertension.  
 
Estraderm  
Estradiol –releasing transdermal system for 
menopausal syndrome for 3 – 4 days. 
  
2. Adhesive Dispersion – Type Systems 
This is a simplified form of the membrane-
permeation controlled system. As represented in 
Fig 6, the drug reservoir is formulated by directly 
dispersing the drug in an adhesive polymer e.g. 
Poly [isobutylene] or poly [acrylate] adhesive and 
then spreading the medicated adhesive, by solvent 
casting or hot melt, on to a flat sheet of drug 
impermeable metallic plastic backing to form a thin 
drug reservoir layer. On the top of the drug 
reservoir layer, thin layers of non-medicated, rate-
controlling adhesive polymer of a specific 
permeability and constant thickness are applied to 
produce an adhesive diffusion – controlled delivery 
system. Examples are: 
Frandol tape  
Releases Isosorbide dinitrate for once-a-day 
medication of angina pectoris.  
Deponit  












3.Matrix Diffusion- Controlled Systems 
In this approach, the drug reservoir is formed by 
homogenously dispersing the drug solids in a 
hydrophilic or lipophillic polymer matrix. The 
resultant medicated polymer is then molded into a 
medicated disc with a defined surface area and 
controlled thickness. The dispersion of drug 
particles in the polymer matrix can be 
accomplished by either homogeneously mixing the 
finely ground drug particles with a liquid polymer 
or a highly viscous base polymer followed by 
cross-linking of the polymer chains or 
homogeneously blending drug solids with a 
rubbery polymer at an elevated temperature. The 
drug reservoir can also be formed by dissolving the 
drug and the polymer in a common solvent 
followed by solvent evaporation in a mould at an 
elevated temperature and/or vacuum. This drug 
reservoir containing polymer disc is then pasted 
onto an occlusive base plate in a compartment 
fabricated from a drug-impermeable plastic 
backing membrane. Instead of applying the 
adhesive polymer directly on the surface of the 
medicated disc as discussed earlier in the first two 
types of transdermal delivery systems, the polymer 
is spread along the circumference of the patch to 
form an adhesive rim around the medicated disc. 
e.g. Nitro-Dur: Delivers nitroglycerin for the 
treatment of angina pectoris. 
 
4.Micro reservoir type or Micro sealed 
Dissolution 
The micro reservoir type drug delivery system can 
be considered a combination of the reservoir and 
matrix diffusion type drug delivery systems. In this 
approach, the drug reservoir is formed by first 
suspending the drug solids in the aqueous solution 
of water soluble liquid polymer [e.g. Polyethylene 
glycol] and then dispersing the drug suspension 
homogenously in lipophillic polymer viz. silicone 
elastomers by high energy dispersion technique to 
form several discrete, unreachable micro spheres of 
drug reservoirs. This thermodynamically unstable 
dispersion is quickly stabilized by immediately 
cross-linking the polymer chains in-situ, which 
produces a medicated polymer disc with a constant 
surface area and a fixed thickness. A transdermal 
therapeutic system is then produced by positioning 
the medicated disc at the centre and surrounding it 
with an adhesive rim. E.g. Nitroglycerin: Releasing 
transdermal therapeutic system for once – a day 
treatment of angina pectoris. 
Evaluation of transdermal films [15-30] 
Evaluation parameters include: 
1. Interaction studies 
2. Thickness of the patch 
3. Weight uniformity 
4. Folding endurance 
5. Percentage Moisture content 
6. Percentage Moisture uptake 
7. Water vapour permeability [WVP] 
evaluation 
8. Drug content 
9. Uniformity of dosage unit test 
10. Polari scope examination 
11. Shear Adhesion test 
12. Peel Adhesion test 
13. Thumb tack test 
14. Flatness test 
15. Percentage Elongation break test 
16. Rolling ball tack test 
17. Quick Stick [peel-tack] test 
18. Probe Tack test 
19. In vitro drug release studies 
20. In vitro skin permeation studies 
            21. Skin Irritation study 
In-Vitro Skin Permeation and Release Kinetics 
Studies:- 
The design and development of transdermal drug 
delivery systems is greatly aided by in vitro studies. 
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In vitro studies can help in investigating the 
mechanism of skin permeation of drug before it can 
be developed into a transdermal therapeutic system. 
The methodology used in the in vitro study is 
relatively easy to follow and generally affords the 
investigator better control over the experimental 
conditions than is possible in-vivo,  
The factors that require consideration when 
selecting an in vitro system include:  
1. The rate limiting process: Drug 
solubilization or diffusion in the vehicle, 
partitioning from the vehicle, diffusion 
through the test membrane or partitioning 
and removal by the receptor phase.  
2. The intrinsic diffusivity of the permeate 
and apparent diffusivity.  
3. The predominating route of diffusion 
during the experiment and the relative 
contents of drug binding and metabolism, 
occurring in the membrane, delivery and 
receptor phases.  
4. The predominating route of diffusion 
during the experimentation and the 
relative extents of drug binding.  
5. The intrinsic barrier potential of the 
membrane and the effects that vehicle 
components may have on retardative 
properties.  
Hydration of the membrane and the presence of 
penetration enhancers may be important here. The 
kinetics of skin permeation can be more precisely 
analyzed by studying the time course for the 
permeation of drug across a freshly excised skin 
mounted on a diffusion cell, such as the Franz 
diffusion cell [Fig 9]. Keshary and Chien have 
pointed out certain deficiencies in the Franz cell 
and modified to obtain closer approximation to in 
vivo conditions [17].Some diffusion cells are 
designed to hold the skin at a vertical position 
between donor and receptor chambers. A more 
recent example is the valia, Chien cell, which is 
superior to similar earlier models in that it does not 
expose both, the donor and the receptor phases to 
the same temperature, and does not allow solvent 
loss from either phase. Moreover, the design 
overcomes another inadequacy of the Franz cell, 
namely the susceptibility of its donor phase to the 
changes in ambient temperature. Finally the donor 
compartment contents may be stirred which makes 
the cell suitable for transdermal drug delivery from 
solutions and suspensions. Various types of in vitro 
apparatus for measuring drug permeation profiles 
across the skin have been reported in the literature. 
They can be broadly classified into two categories 
as shown below.  
A. Physical design of diffusion cell  
  Horizontal type  
  Vertical type  
  Flow-through type 
  
B. Method of sampling and measurement  
 Continuing system  
 Fluid circulation system  
 Non circulation system  
 Intermittent system:  
 rotating agitation systems  
1. Donor Compartment  
 Easy access to deliver the penetrant to the skin.  
 Stirred were possible.  
 Temperature controlled [32 OC + 1 OC]  
 Control of evaporation for vehicles and 
penetrant  
2. Membrane  
 For the study of penetration kinetics, only 
human skin should be used.  
 For vehicle/device release studies other 
barrier may be used.  
 The skin sample should contain both 
stratum corneum and viable epidermis.  
 A molecule of known penetration kinetics 
should used prior to the test molecule, to assess 
barrier function.  
3. Receptor Compartment  
 Either, flow – through or static.  
 Temperature controller [32 0C + 10C]  
 Sufficient volume to maintain infinite sink 
conditions 
  Stirred without obvious formations of 
boundary layers.  
 
4. Receptor Fluid 
 Should not compromise barrier function.  
 Should be of favorable partitioning.  
 Capable of maintaining epidermal 
viability where ever necessary.  
 Must be contained once collected. 
Majority of In vitro experiments are conducted in 
animal skin i.e. hairless mouse, guinea, rabbit etc. 
Although these exist a number of similarities there 
is as yet no animal skin that complete mimics the 
penetration characterization of human skin. 
 
In-vivo Evaluation of Transdermal Drug 
Delivery:- 
Systems: In-vivo evaluation of TDDS can be 
carried out using,  
A. Animal models  
B. Human volunteers  
C. Biophysical models  
A. Animal models  
In vivo animal models are preferred because 
considerable time and resources are required to 
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carry out studies in humans. Some of the species 
that have been used for in vivo testing include; 
mouse, rat, guinea pig, rabbit, hairless mouse, 
hairless rat, hair less dog, cat, dog, miniature pig, 
pig, horse, goat, squirrel, monkey, rhesus monkey, 
chimpanzee, etc. Various experiments have been 
carried out to determine which of the animal 
models provide the best prediction of the behavior 
of the device, being tested, in humans.  
 
B. Human volunteers  
The final stage in the development of transdermal 
device involves collection of pharmacokinetic and 
pharmacodynamic data following application of the 
device to human volunteers. An in vivo evaluation 
using human subjects should give pertinent 
information with minimum risk to the subjects 
within a reasonable period of time. In vivo 
evaluation using human models involve 
determination of percutaneous absorption by an 
indirect method of measuring radio activity in 
excreta following topical application of the labeled 
drug. C-14 is generally used for radio-labelling 
Determination of absorption following topical 
administration requires the investigator to know the 
amount of radioactivity retained in the body, or 
excreted by routes not monitored. This necessitates 
measurement of dose absorbed. However this 
method has certain limitations, to overcome the 
limitations inherent in this method, various 
refinements have been made. These are described 
below 
 
1. Reservoir Technique  
This method involves a simple, short exposure of 
the skin to the [radio-labeled] compound under 
study followed by removal of the stratum corneum 
by tape stripping and analysis of the content of the 
compound in the stratum corneum. From this 
analysis, it is possible to predict the amount of drug 
that will penetrate over a longer period of time.  
 
2. Mass balance Technique  
This method involves the application site is 
covered with an occlusive chamber, the chamber 
being replaced by a new one after a particular time 
interval. The site is also subjected to washing at 
these times. Radio-labeling techniques are used and 
the chambers, washings and the faces and urine of 
the patients are subjected to analysis. Advantage of 
this technique include achievement of mass balance 
between the applied dose and excretion levels and 
the use of surface wash measurements for 
predicting percutaneous absorption.  
 
C. Biophysical Models  
Models based on steady-state mass balance 
equation, solution of Fick‟s second law of diffusion 
for the device, stratum corneum and viable 
epidermis, as well as linear kinetics have been 
described in the literature. It can be concluded that 
many techniques for in-vivo evaluation of 
transdermal systems have been put forward there is 
scope for further refinement. Some of the 
unresolved issues include the barrier function of the 
skin with age, skin metabolism, in-vivo functioning 
of penetration enhancers etc. 
 
METHODS TO ENHANCE TRANSDERMAL 
DELIVERY [31, 32,33] 
1.Chemical enhancers- Because the skin provides 
such a formidable barrier to the delivery of most 
drugs, a broad range of different chemical additives 
have been tested to enhance transdermal 
penetration. chemical penetration enhancers 
provide certain advantages, including design 
flexibility with formulation chemistry and an easier 
possibility of patch application over a large area 
[>10 cm2]. Chemical penetration enhancers can 
increase skin permeability by various mechanisms, 
including enhancing solubility, increasing 
partitioning into the stratum corneum, fluidizing 
the crystalline structure of stratum corneum and 
causing dissolution of stratum corneum lipids. 
Example - Surfactants [Tween], fatty acids/esters 
[oleic acid], terpenes [limonene], and solvents 
[dimethyl sulphoxide and ethanol].  
 
limitation - potent chemical enhancers are usually 
potent irritants to the skin at concentrations 
necessary for achieving useful levels of penetration 
enhancement and are therefore physiologically 
incompatible  
 
2.Iontophoresis: - Rates of transdermal transport 
can also be increased through Iontophoresis, which 
uses an electric field to move both charged and 
uncharged species across the skin. Transdermal 
iontophoresis has been most extensively applied to 
the delivery of anti-inflammatory agents and other 
compounds for local effects in the context 
of physical therapy. Other FDA-approved uses 
include pilocarpine delivery to induce sweating as 
part of a cystic fibrosis diagnostic test, tap-water 
delivery to treat hypperhydrosis, lidocaine delivery 
for local anesthesia, especially before venipuncture, 
and extraction 
of interstitial fluid for monitoring glucose levels in 
diabetics. Typically, a few milli amperes of current 
are applied to a few square centimeters of skin, 
which generally causes no pain or irritation beyond 
mild erythema. Iontophoresis can enhance transport 
across skin by a number of possible mechanisms, 
including an electrophoretic driving force, an 
electro osmotic driving force, and transiently 
increased skin permeability. The electrophoretic 
mechanism can drive charged compounds across 
the skin by a direct interaction with the electric 
field. Species with greater charge and smaller 
molecular mass are generally delivered more 
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rapidly. Enhancement by electro-osmosis involves 
the delivery of molecules that are dragged by 
electrically induced solvent flow. 
 
3. Electroporation: - Another approach to increase 
transdermal transport using electric fields involves 
the application of short, high voltage pulses to the 
skin to transiently increase skin permeability by a 
mechanism related to electroporation. Transdermal 
transport has been shown to increase by orders of 
magnitude using electroporation, with partial 
Reversibility within seconds and full reversibility, 
in some cases, within minutes to hours. The largest 
fluxes have been observed for synthetic molecules 
and small macromolecules [<10 kDa], including a 
clinical study of lidocaine delivery in humans. 
Larger macromolecules have also been delivered, 
including heparin, insulin, vaccines, 
oligonucleotides, DNA and microparticles, in 
which electroporation combined with chemical-
enhancement methods have been most effective 
 
4.Sonophoresis :- Ultrasonic waves, as well as 
short-duration shock waves, have been used to 
facilitate transdermal drug delivery. ultrasound at 
various frequencies in the range of 20 kHz–16 
MHz has been used to enhance skin permeability 
by a method called SONOPHORESIS. 
Traditionally, ultrasound at high frequencies [f >1 
MHz, therapeutic ultrasound] was a popular choice 
for sonophoresis. Since Fellinger and Schmidt 
reported the treatment of polyarthritis of the digital 
joints of the hand using hydrocortisone ointment 
with therapeutic ultrasound in the 1950s, 
sonophoresis has been used to facilitate topical 
drug delivery, especially in the context of physical 
therapy. Low-frequency sonophoresis has been 
shown to enhance in vitro transdermal transport of 
a variety of high-molecular mass drugs, including 
insulin, erythropoeitin, interferon and low-
molecular weight heparin. The efficacy of low-
frequency sonophoresis to deliver macromolecules 
has also been demonstrated in vivo for insulin, for 
low-molecular weight heparin in animals and 
recently in human volunteers for topical delivery of 
local anaesthetics. In one of its modes, low-
frequency ultrasound has been shown to quickly 
permeabilize human skin and maintain it in a state 
of high permeabilization for a number of hours, 
thereby opening a window for drug delivery using a 
simple patch. Enhanced skin permeability during 
low-frequency sonophoresis has also been used to 
extract glucose and other constituents of interstitial 
fluid across permeabilized skin.  
Several possible mechanisms of sonophoresis have 
been investigated.  
 First, thermal effects due to absorption of 
ultrasound by the skin;  
 acoustic streaming caused by development 
of time-independent fluid velocities in the skin due 
to ultrasound;  
 cavitational effects due to the formation, 
oscillation and possible collapse of bubbles in or 
next to the skin. Among these, cavitation was found 
to be primarily responsible.  
 
5.Microneedles [34]:- Recently, arrays of 
microscopic needles have been used for 
transdermal drug delivery. Needles of micron 
dimensions can pierce into the skin surface to 
create holes large enough for molecules to enter, 
but small enough to avoid pain or significant 
damage. In vitro experiments have shown that 
inserting microneedle into skin can increase 
permeability by orders of magnitude for small 
drugs, large macromolecules and nanoparticles. 
Animal experiments have similarly shown large 
increases in transdermal delivery of compounds, 
including oligonucleotides, insulin, desmopressin 
and human growth hormone. Microneedle-based 
delivery of vaccines, including proteins and DNA, 
is of special interest, in part to target langerhans 
cells in the skin’s epidermis.Human studies have 
shown that microneedles are reported as painless 
when inserted into the skin of human subjects. A 
number of Fortune 500 corporations, as well as 
startup companies, are actively developing 
microneedles for transdermal drug delivery. This 
can be carried out as a pretreatment to increase skin 
permeability before the subsequent application of a 
drug-loaded patch.Alternatively, microneedles can 
be coated with drug that is released from the 
needles while they are embedded in the 
skin.Hollow microneedles have also been 
fabricated and used to flow drug solutions into the 
skin. 
 
GENERAL CLINICAL CONSIDERATION IN 
USE OF TDDS 
The patient should be advised of the following 
general guidelines. The patient should be advised 
of the importance of using the recommended site 
and rotating locations within the site. Rotating 
location is important to allow the skin to regain its 
normal permeability and to prevent skin irritation. 
1. TDDS should be applied to clean, dry skin 
relatively free of hair and not oily, inflamed, 
irritated, broken. Wet or moist skin can 
accelerate drug permeation time. Oily skin 
can impair the adhesion of patch. If hair is 
present at the site, it should be carefully cut, 
not wet shaved nor should a depilatory agent 
be used, since later can remove stratum 
corneum and affect the rate and extent of drug 
permeation. 
2. Use of skin lotion should be avoided at the 
application site, because lotions affect the 
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hydration of skin and can alter partition 
coefficient of drug. 
3. Patient should not physically alter TDDS, 
since this destroys integrity of the system. 
4. The protecting backing should be removed 
with care not to touch fingertips. The TDDS 
should be pressed firmly against skin site with 
the heel of hand for about 10 seconds. 
5. A TDDS should be placed at a site that will 
not subject it to being rubbed off by clothing 
or movement. TDDS should be left on when 
showering, bathing or swimming. 
6.  A TDDS should be worn for full period as 
stated in the product’s instructions followed 
by removal and replacement with fresh 
system. 
7. The patient or caregiver should clean the 
hands after applying a TDDS. Patient should 
not rub eye or touch the mouth during 
handling of the system. 
8. If the patient exhibits sensitivity or 
intolerance to a TDDS or if undue skin 
irritation results, the patient should seek 
reevaluation. 
9. Upon removal, a used TDDS should be 
folded in its half with the adhesive layer 
together so that it cannot be reused. The used 
patch discarded in a manner safe to children 
and pets. 
EFFECT OF HEAT ON TRANSDERMAL 
PATCH [35] 
Heat is known to increase skin permeation of drugs 
by several mechanisms. Higher temperatures 
increase microcirculation and blood vessel 
permeability, which facilitates drug transfer into 
the systemic circulation. A rise in temperature may 
also increase drug solubility both in the patch 
formulation and within the skin, thus increasing the 
release rate of the drug from local skin tissue into 
the systemic circulation. In fact, a new technology 
utilizing heat's ability to increase transdermal 
permeation called the controlled, heat-aided drug 
delivery [CHADD] system is currently under 
review by the FDA. Since heat increases skin 
permeation, there are concerns that excessive 
exposure to heat will increase absorption of 
transdermally delivered drugs and lead to 
overdosage. In fact, the U.S. prescribing 
information for Duragesic warns patients to avoid 
exposing the application site to direct external heat 
sources, such as heating pads or electric blankets, 
heat lamps, saunas, hot tubs, and heated water beds, 
etc., while wearing the patch. In addition, the 
Canadian Duragesic drug monograph also warns 
patients to avoid hot water bottles, hot whirlpool 
spa baths, and intensive sun-bathing. A 
pharmacokinetic model showed that serum fentanyl 
concentrations could theoretically increase by 
approximately one-third for patients with a body 
temperature of 40°C [104°F]. Therefore, the 
manufacturer also recommends close monitoring 
for opioid side effects in patients who have 
developed fevers while wearing a Duragesic patch. 
Heat-induced increased absorption of transdermally 
delivered drugs is well documented. However, 
many patients are not aware of the possibility of 
overdosing on transdermally delivered drugs when 
the application site is exposed to heat. It is 
important to educate patients about this possibility 
to prevent drug overdose and/or compromise 
efficacy. Patients should be advised to avoid 
exposing the patch application site to external heat 
sources including, but not limited to, heating pads 
or electric blankets, heat lamps, saunas, hot tubs, 
heated water beds, hot water bottles, hot whirlpool 
spa baths, and intensive sun-bathing. They should 
also be advised that fever and an increase in body 
temperature from intense physical activity may also 
increase the absorption of transdermally delivered 
drugs. In the event of drug overdose, the drug patch 
should be removed immediately and appropriate 
treatment measures should be employed. Patients 
should also be reminded to store transdermal drug 
patches in their original packaging and keep in a 
cool, dry place until they are ready to be used.   
APPLICATION OF TRANSDERMAL 
PATCHES [1,2,8] 
 The highest selling transdermal patch in the 
United States is the nicotine patch, which 
releases nicotine in controlled doses to help 
with cessation of tobacco smoking.  
 Two opioid medications used to provide 
round-the-clock relief for severe pain are often 
prescribed in patch form: Fentanyl [marketed 
as Duragesic] and Buprenorphine [marketed as 
BuTrans]. 
 Estrogen patches are sometimes prescribed to 
treat menopausal symptoms as well as post-
menopausal osteoporosis. Other transdermal 
patches for hormone delivery include the 
contraceptive patch [marketed as Ortho Evra or 
Evra].  
 Nitroglycerin patches are sometimes 
prescribed for the treatment of angina in lieu of 
sublingual pills.  
 The anti-hypertensive drug Clonidine is 
available in transdermal patch form.  
 Transdermal form of the MAOI selegiline, 
became the first transdermal delivery agent for 
an antidepressant.  
 Transdermal delivery agent for the Attention 
Deficit Hyperactivity Disorder [ADHD].  
 
TRANSDERMAL MARKET PRODUCT 
[13,14] 
The market for transdermal products has been in a 
significant upward trend that is likely to continue 
for the foreseeable future. An increasing number of 
TDD products continue to deliver real therapeutic 
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benefit to patients around the world. More than 35 
TDD products have now been approved for sale in 
the US, and approximately 16 active ingredients are 
approved for use in TDD products globally. Drug 
in adhesive technology has become the preferred 
system for passive transdermal delivery; two areas 
of formulation research are focused on adhesives 
and excipients. Adhesive research focuses on 
customizing the adhesive to improve skin adhesion 
over the wear period, improve drug stability and 
solubility, reduce lag time, and increase the rate of 
delivery. Because a one-size-fits-all adhesive does 
not exist that can accommodate all drug and 
formulation chemistries, customizing the adhesive 
chemistry allows the transdermal formulator to 
optimize the performance of the transdermal patch. 
A rich area of research over the past 10 to 15 years 
has been focused on developing transdermal 
technologies that utilize mechanical energy to 
increase the drug flux across the skin by either 
altering the skin barrier [primarily the stratum 
corneum] or increasing the energy of the drug 
molecules. These so-called “active” transdermal 
technologies include iontophoresis [which uses low 
voltage electrical current to drive charged drugs 
through the skin], electroporation [which uses short 
electrical pulses of high voltage to create transient 
aqueous pores in the skin], sonophoresis [which 
uses low frequency ultrasonic energy to disrupt the 
stratum corneum], and thermal energy [which uses 
heat to make the skin more permeable and to 
increase the energy of drug molecules]. Even 
magnetic energy, coined magnetophoresis, has 
been investigated as a means to increase drug flux 
across the skin. 






































Advancement in tdds [13, 14] 
Drug in adhesive technology has become the 
preferred system for passive transdermal delivery; 
two areas of formulation research are focused on 
adhesives and excipients. Adhesive research 
focuses on customizing the adhesive to improve 
skin adhesion over the wear period, improve drug 
stability and solubility, reduce lag time, and 
increase the rate of delivery. Because a one-size-
fits-all adhesive does not exist that can 
accommodate all drug and formulation chemistries, 
customizing the adhesive chemistry allows the 
transdermal formulator to optimize the 
performance of the transdermal patch. A rich area 
of research over the past 10 to 15 years has been 
focused on developing transdermal technologies 
that utilize mechanical energy to increase the drug 
flux across the skin by either altering the skin 
barrier [primarily the stratum corneum] or 
increasing the energy of the drug molecules. These 
so-called “active” transdermal technologies include 
iontophoresis [which uses low voltage electrical 
current to drive charged drugs through the skin], 
electroporation [which uses short electrical pulses 
of high voltage to create transient aqueous pores in 
the skin], sonophoresis [which uses low frequency 
ultrasonic energy to disrupt the stratum corneum], 
and thermal energy [which uses heat to make the 
skin more permeable and to increase the energy of 
drug molecules]. Even magnetic energy, coined 
magnetophoresis, has been investigated as a means 
to increase drug flux across the skin. 
 
CONCLUSION:  
Successful transdermal drug application requires 
numerous considerations. Bearing in mind that the 
basic functions of the skin are protection and 
containment, it would seem exceptionally difficult 
to target the skin for drug delivery. However, with 
our greater understanding of the structure and 
function of the skin, and how to alter these 
properties, more and more new drug products are 
being developed for transdermal delivery. The 
properties of the drug, the characteristics of the 
transdermal device, selection of in-vivo model and 
the status of patient’s skin are all important for safe 
and effective drug delivery. Taking into account the 
advantages of TDDS, it can be considered a perfect 
alternative for drugs whose enteral and parenteral 
dosages forms having drawbacks in performance 
and also in patient compliance. After rectifying the 
presently excisting short-comings TDDS can surely 
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